What is ICCM's current stock price?

ICCM (IceCure Medical Ltd) is currently trading at $0.24 with a market cap of $15.8M.

What sector is IceCure Medical Ltd in?

IceCure Medical Ltd (ICCM) operates in the Healthcare sector, specifically in the Medical - Devices industry.

Is ICCM a good stock to buy?

Analysts have a Buy consensus on ICCM with a price target of $1.00. Check our detailed analysis for valuation, financials, and insider activity.

InvestLog

ICCM IceCure Medical Ltd

Healthcare

$0.23-0.30%ClosedMarket Cap: $15.8M

As of 2026-05-25

Valuation

View Details

P/E (TTM)

—

PEG

—

P/B

2.04

P/S

4.43

EV/EBITDA

-0.51

DCF Value

$-0.36

FCF Yield

-97.0%

Div Yield

0.0%

Margins & Returns

Gross Margin

36.5%

Operating Margin

-835.0%

Net Margin

-441.6%

ROE

-211.7%

ROA

-118.3%

ROIC

-344.8%

Financials

View All

Period	Revenue	Net Income	EPS
Q1 null	$911.0K	$-4.3M	$—
Q4 null	$1.3M	$-4.2M	$—
FY null	$3.4M	$-15.1M	$—
Q3 null	$850.0K	$-3.9M	$—

Analyst Ratings

View All

Consensus

Buy

Target (Consensus)

$1.00

Target (Median)

$1.00

Target Range

$1.00 - $1.00

1 Strong Buy2 Buy0 Hold0 Sell0 Strong Sell

Maxim GroupBuy

2026-05-14

HC Wainwright & Co.Buy

2025-10-07

HC Wainwright & Co.Buy

2025-08-15

HC Wainwright & Co.Buy

2025-05-29

Trading Activity

Insider Trades

View All

Tsimerman Ronenofficer

SellMon May 18

Peleg Meirofficer: Chief Financial Officer

SellMon May 18

Muchnik Naumofficer

SellMon May 18

Tel-Tzure Tlalit Bussiofficer: VP, BD & Global Marketing

SellWed Mar 25

Tel-Tzure Tlalit Bussiofficer: VP, BD & Global Marketing

SellWed Mar 25

Latest News

IceCure Reports Positive 5-Year Top-Line Results from ICESECRET Kidney Cancer Cryoablation Study: 89.4% and 83.9% Recurrence-Free RatesPRNewsWire · Wed Mar 25

Company Info

Sector

Healthcare

Industry

Medical - Devices

Country

Exchange

—

Beta

1.63

IceCure Medical Ltd, a medical device company, engages in the research, development, and commercialization of medical devices for cryoablation (freezing) of tumors in the human body. It offers ProSense system, a cryoablation solution for the treatment of breast tumors. The company was incorporated in 2006 and is headquartered in Caesarea, Israel.

Peers